Published in Vaccine Weekly, January 23rd, 2008
"Recombinant lentivectors are now being developed and evaluated as antigen delivery platforms for genetic immunization and immune engineering. Early results from studies utilizing lentivectors are promising. Third generation lentivectors have been engineered to improve biosafety and reduce antivector immune responses. The ability of third generation lentivectors to efficiently transduce non-dividing cells, including...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly